Human amniotic membrane products for patients with diabetic foot ulcers. do they help? a systematic review and meta‐analysis

Abstract

Abstract Background Diabetic foot ulcer (DFU) is one of the most serious diabetic complications. DFU is an open wound that usually occurs in the foot sole due to poor blood glucose control, peripheral neuropathy, and poor circulation. The human amniotic allograft membrane is a biological wound dressing derived from the amniotic membrane. It contains amino acids, nutrients, cytokines, and growth factors that make the growth process easier. Objective To compare dehydrated human amnion and chorion allograft (DHACA) plus the standard of wound care (SOC) with the SOC alone. Methods We searched for randomized clinical trials (RCTs) on PubMed, Scopus, Cochrane, and Web of Science till April 2021 using relevant keywords. All search results were screened for eligibility. We extracted the data from the included trials and pooled them as mean difference (MD) or risk ratio (RR) with the 95% confidence interval (CI) using Review Manager software (ver. 5.4). Results The pooled effect estimate from 11 RCTs showed that DHACA was superior to SOC regarding the complete wound healing in both 6th and 12th week (RR = 3.78; 95% CI: [2.51, 5.70]; P < 0.00001) and (RR = 2.00; 95% CI: [1.67, 2.39], P < 0.00001 respectively). Also, the analysis favored the DHACA regarding the mean time to heal in the 12th‐week (MD = ‐12.07, 95%CI: [‐19.23, ‐4.91], P = 0.001). The wound size reduction was better with DHACA (MD = 1.18, 95%CI: [‐0,10, 2.26], P = 0.03). Conclusion Using DHACA with SOC is safer and more effective than using SOC alone for DFU patients.

Keywords

• Diabetic foot ulcer
• Human amnion membrane
• Amniotic allograft
• Grafix
• AmnioBand
• EpiFix